Bone Microthrombus Promotes Bone Loss in Iron Accumulation Rats

Abstract

In the present study, we investigated the changes of the coagulation state, bone microthrombus, microvascular bed and bone density levels in iron accumulation rats. Meanwhile,the effect of anticoagulation therapy on bone mineral density was further investigated. We established two groups: a control (Ctrl) group and an iron intervention (FAC) group. Changes in coagulation function, peripheral blood cell counts, bone microthrombus, bone vessels and bone mineral density were compared between the two groups. We designed the non-treatment group and treatment group to study the changes of bone mineral density by preventing microthrombus formation with the anticoagulant fondaparinux. We found that the fibrinogen and D-dimer contents were significantly higher, whereas the thrombin time (TT) and prothrombin time (PT) were significantly shorter in the FAC group. After ink staining, the microvascular bed in the FAC group was significantly reduced compared with that in the Ctrl group. HE and Martius Scarlet Blue (MSB) staining showed microthrombus in the bone marrow of the iron accumulation rats. Following anticoagulation therapy, the bone microcirculation vascular bed areas in the treatment group rats were significantly increased. Furthermore, the bone mineral density was increased in the treatment group compared with that in the non-treatment group. Through experiments, we found that the blood in iron accumulation rat was relatively hypercoagulable; moreover, there was microthrombus in the bone marrow, and the bone vascular bed was reduced. Additionally, anticoagulation was helpful for improving bone microcirculation, reducing microthrombus and decreasing bone loss.

Keywords

iron accumulation / osteoporosis / coagulation state / microvascular bed / bone microthrombus / anticoagulant

References

[1] HorwitzLD, RosenthalEA. Iron-mediated cardiovascular injury. Vasc Med, 1999, 4(2): 93-99

[2] SalonenJT, NyyssonenK, KorpelaH, et al.. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation, 1992, 86(3): 803-811

[3] de ValkB, AddicksMA, GosriwatanaI, et al.. Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest, 2000, 30(3): 248-251

[4] TuomainenTP, KontulaK, NyyssonenK, et al.. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in Eastern Finland. Circulation, 1999, 100(12): 1274-1279

[5] RoestM, van der SchouwYT, de ValkB, et al.. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation, 1999, 100(12): 1268-1273

[6] DaySM, DuquaineD, MundadaLV, et al.. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation, 2003, 107(20): 2601-2606

[7] SarraiM, DuroseauH, D’AugustineJ, et al.. Bone mass density in adults with sickle cell disease. Br J Haematol, 2007, 136(4): 666-672

[8] GuggenbuhlP, DeugnierY, BoisdetJF, et al.. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporosis International, 2005, 16(12): 1809-1814

[9] KimBJ, AhnSH, BaeSJ, et al.. Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: a 3-year retrospective longitudinal study. J Bone Miner Res, 2012, 27(11): 2279-2290

[10] WeinbergED. Iron loading: a risk factor for osteoporosis. Biometals, 2006, 19(6): 633-635

[11] YuanY, XuF, CaoY, et al.. Iron Accumulation Leads to Bone Loss by Inducing Mesenchymal Stem Cell Apoptosis Through the Activation of Caspase3. Biol Trace Elem Res, 2019, 187(2): 434-441

[12] SchlittA, BuerkeM, HauroederB, et al.. Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thromb Haemost, 2003, 90(2): 245-251

[13] DemirtasA, AzboyI, BulutM, et al.. Investigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats. Eur Rev Med Pharmacol Sci, 2013, 17(14): 1850-1856

[14] FischerF, Appert-FloryA, JambouD, et al.. Evaluation of the automated coagulation analyzer Sysmex CA-7000. Thromb Res, 2006, 117(6): 721-729

[15] HuangLF, ShiHL, GaoB, et al.. Decichine enhances hemostasis of activated platelets via AMPA receptors. Thromb Res, 2014, 133(5): 848-854

[16] WellsPS, Brill-EdwardsP, StevensP, et al.. A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation, 1995, 91(8): 2184-2187

[17] FreyburgerG, TrillaudH, LabroucheS, et al.. D-dimer strategy in thrombosis exclusion—a gold standard study in 100 patients suspected of deep venous thrombosis or pulmonary embolism: 8 DD methods compared. Thromb Haemost, 1998, 79(1): 32-37

[18] Brill-EdwardsP, LeeA. D-dimer testing in the diagnosis of acute venous thromboembolism. Thromb Haemost, 1999, 82(2): 688-694

[19] van der HulleT, den ExterPL, ErkensPG, et al.. Variable D-dimer thresholds for diagnosis of clinically suspected acute pulmonary embolism. J Thromb Haemost, 2013, 11(11): 1986-1992

[20] FavresseJ, LippiG, RoyPM, et al.. D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications. Crit Rev Clin Lab Sci, 2018, 55(8): 548-577

[21] DonahueDL, BeckJ, FritzB, et al.. Early platelet dysfunction in a rodent model of blunt traumatic brain injury reflects the acute traumatic coagulopathy found in humans. J Neurotrauma, 2014, 31(4): 404-410

[22] Arias-NegreteS, Jiménez-RomeroLA, Solís-MartínezMO, et al.. Indirect determination of nitric oxide production by reduction of nitrate with a freeze-thawing-resistant nitrate reductase from Escherichia coli MC1061. Anal Biochem, 2004, 328(1): 14-21

[23] LuM, LiuY, ShaoM, et al.. Associations of Iron Intake, Serum Iron and Serum Ferritin with Bone Mineral Density in Women: The National Health and Nutrition Examination Survey, 2005–2010. Calcif Tissue Int, 2020, 106(3): 232-238

[24] OrinoK, LehmanL, TsujiY, et al.. Ferritin and the response to oxidative stress. Biochem J, 2001, 357: 241-247 Pt 1)

[25] JungDW, ParkJH, KimDH, et al.. Association between serum ferritin and hemoglobin levels and bone health in Korean adolescents: A nationwide population-based study. Medicine (Baltimore), 2017, 96(51): e9403

[26] DaleJC, BurrittMF, ZinsmeisterAR. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. Am J Clin Pathol, 2002, 117(5): 802-808

[27] ValentiL, VarennaM, FracanzaniAL, et al.. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int, 2009, 20(4): 549-555

[28] RossiF, PerrottaS, BelliniG, et al.. Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica, 2014, 99(12): 1876-1884

[29] SiL, WinzenbergTM, ChenM, et al.. Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study. Osteoporos Int, 2016, 27(7): 2259-2269

[30] MilmanN, KirchhoffM. Iron stores in 1359, 30- to 60-year-old Danish women: evaluation by serum ferritin and hemoglobin. Ann Hematol, 1992, 64(1): 22-27

[31] KimBJ, LeeSH, KohJM, et al.. The association between higher serum ferritin level and lower bone mineral density is prominent in women S45 years of age (KNHANES 2008–2010). Osteoporosis International, 2013, 24(10): 2627-2637

[32] WangX, ChenB, SunJ, et al.. Iron-induced oxidative stress stimulates osteoclast differentiation via NF-κB signaling pathway in mouse model. Metabolism, 2018, 83: 167-176

[33] JiaP, XuYJ, ZhangZL, et al.. Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species. J Orthop Res, 2012, 30(11): 1843-1852

[34] XiaoW, BeibeiF, GuangsiS, et al.. Iron overload increases osteoclastogenesis and aggravates the effects of ovariectomy on bone mass. J Endocrinol, 2015, 226(3): 121-134

[35] GowAJ, FarkouhCR, MunsonDA, et al.. Biological significance of nitric oxide-mediated protein modifications. Am J Physiol Lung Cell Mol Physiol, 2004, 287(2): L262-268

[36] RussoG, LeopoldJA, LoscalzoJ. Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vascul Pharmacol, 2002, 38(5): 259-269

[37] PechánováO, SimkoF. The role of nitric oxide in the maintenance of vasoactive balance. Physiol Res, 2007, 56(Suppl2): S7-S16

[38] TufanoA, CoppolaA, ContaldiP, et al.. Oral anticoagulant drugs and the risk of osteoporosis: new anticoagulants better than old?. Semin Thromb Hemost, 2015, 41(4): 382-388

[39] SignorelliSS, ScutoS, MarinoE, et al.. Anticoagulants and Osteoporosis. Int J Mol Sci, 2019, 20(21): 5275

[40] MuirJM, AndrewM, HirshJ, et al.. Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in Vivo. Blood, 1996, 88(4): 1314-1320

[41] MuirJM, HirshJ, WeitzJI, et al.. A histomorphometric comparison of the effects of heparin and low-molecular weight heparin on cancellous bone in rats. Blood, 1997, 89(9): 3236-3242

[42] JohnstonA, HsiehSC, CarrierM, et al.. A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making. PLoS One, 2018, 13(11): e0207410

[43] LindnerT, CockbainAJ, El MasryMA, et al.. The effect of anticoagulant pharmacotherapy on fracture healing. Expert Opin Pharmacother, 2008, 9(7): 1169-1187

[44] PapathanasopoulosA, KouroupisD, HenshawK, et al.. Effects of antithrombotic drugs fondaparinux and tinzaparin on in vitro proliferation and osteogenic and chondrogenic differentiation of bone-derived mesenchymal stem cells. J Orthop Res, 2011, 29(9): 1327-1335

[45] Alban S. Adverse effects of heparin. Handb Exp Pharmacol, 2012,(207):211–263